Published in Law and Health Weekly, April 2nd, 2005
The ARISE phase III clinical trial is testing the company's lead compound, AGI-1067, for the oral treatment of atherosclerosis in leading cardiovascular research centers throughout the United States, Canada, the United Kingdom and South Africa.
The changes to the ARISE protocol are intended to enhance the trial as well as to accelerate its pace, without adversely affecting its Special Protocol...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.